Abstract 10383: Comparative Assessment of Medical Therapy, PCI, or CABG on Clinical Outcomes in Diabetic Patients With Stable CAD According to Coronary Angiography and Left Ventricular Function: Patient-level Meta-analysis of the BARI-2D, COURAGE, and FREEDOM Trials
Introduction: The benefits of optimal medical therapy (OMT) with or without percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery have been evaluated in patients with Type 2 Diabetes Mellitus (T2DM) and stable coronary artery disease (CAD) but analyses have not been stratified by detailed angiographic CAD burden or left ventricular ejection fraction (LVEF).
Methods: A patient-level meta-analysis was undertaken among T2DM patients enrolled in COURAGE, BARI 2D and FREEDOM to assess the impact of randomization to OMT, PCI + OMT, or CABG + OMT on a composite end-point of Death/MI/Stroke and stratified by LVEF (≥ 50%, < 50%), 1, 2 or 3 vessel disease (VD) (% diameter stenosis ≥ 50%) and presence or absence of proximal left anterior descending (pLAD) disease. Hazard ratios (HR) for treatment groups were calculated from Cox regression models including all patients adjusting for trial and revascularization stratum in BARI 2D. Multivariable adjustment for risk factors was performed as a sensitivity analysis.
Results: There were 5,034 patients included in the analysis (BARI 2D: n=2,368, COURAGE: n=766, FREEDOM: n=1,900) of whom 17% had LVEF < 50%, 29% had pLAD, and 77% had 2 or 3 VD. A total of 1,591 patients were randomized to OMT alone, 2,118 to PCI + OMT, and 1,325 to CABG + OMT. There were 1,116 events during a median 4.5 year follow-up. There was no significant effect on outcomes with OMT vs PCI + OMT irrespective of LVEF, presence/absence of pLAD and number of VD. By contrast, CABG + OMT significantly reduced the risk of Death/MI/Stroke in patients with 2 or 3 VD, irrespective of LVEF and presence/absence of pLAD (see Table). Results were similar with multivariable adjustment.
Conclusions: In patients with T2DM and stable CAD, OMT alone appears to be as effective as PCI + OMT while CABG + OMT significantly reduces cardiovascular events in those with multivessel CAD, irrespective of LVEF or presence of pLAD.
- diabetes mellitus
- percutaneous coronary intervention
- coronary artery bypass grafting
- clinical trials
Author Disclosures: G. Mancini: Honoraria; Modest; Regeneron. Consultant/Advisory Board; Modest; AMGEN, Sanofi, Merck. M.E. Farkouh: None. B.R. Chaitman: Speakers Bureau; Modest; Gilead. Speakers Bureau; Significant; Modest. Consultant/Advisory Board; Modest; Merck, Sanofi, NovoNordisk, Lilly. Consultant/Advisory Board; Significant; Modest, Significant, Significant, Modest. W.E. Boden: Research Grant; Modest; Abbvie, Amgen. Research Grant; Significant; Modest, Modest. Speakers Bureau; Modest; Janssen, Merck, Sanofi. Speakers Bureau; Significant; Modest, Modest, Modest. Honoraria; Modest; Janssen, Merck, Sanofi, Gilead. Honoraria; Significant; Modest, Modest, Modest, Modest. Consultant/Advisory Board; Modest; Arisaph, CardioDx, Merck, Sanofi. Consultant/Advisory Board; Significant; Modest, Modest, Modest, Modest. R.L. Frye: None. P.M. Hartigan: None. H. Vlachos: None. F.S. Siami: Research Grant; Modest; Cordis. Research Grant; Significant; Significant. M.S. Sidhu: None. V.A. Bittner: Research Grant; Modest; Bayer Healthcare, Janssen. Research Grant; Significant; significant, significant. Honoraria; Modest; Sanofi, Amgen, Astra Zeneca. Honoraria; Significant; modest, modest, modest. Consultant/Advisory Board; Modest; Eli Lilly, Amgen. Consultant/Advisory Board; Significant; modest, modest. V. Fuster: None. M.M. Brooks: Research Grant; Modest; Gilead. Research Grant; Significant; Significant.
- © 2015 by American Heart Association, Inc.